Preclinical Pharmacology of Fiduxosin, a Novel α1-Adrenoceptor Antagonist with Uroselective Properties
Authors:
- Arthur A. HancockAHArthur A. Hancock
- Steven A. BucknerSBSteven A. Buckner
- Michael E. BruneMBMichael E. Brune
- Timothy A. EsbenshadeTETimothy A. Esbenshade
- Lynne M. IrelandLILynne M. Ireland
- Sweta KatwalaSKSweta Katwala
- Ivan MilicicIMIvan Milicic
- Michael D. MeyerMMMichael D. Meyer
- James F. KerwinJKJames F. Kerwin
- Michael WilliamsMWMichael Williams
- 1 February 2002
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 300 (2) , 478-486
Abstract
Benign prostatic hyperplasia (BPH), common in aging males, is often treated with α1-adrenoceptor antagonists. To minimize hypotensive and other side effects, compounds with selective antagonist activity at α1A- and α1D- (compared with α1B-) adrenoceptors were evaluated that would block lower urinary tract α1-adrenoceptors in preference to cardiovascular α1B-adrenoceptors. Fiduxosin (3-[4-((3aR,9bR)-cis-9-methoxy-1,2,3,3a,4,9b-hexahydro-[1]-benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenyl-pyrazino[2′,3′:4,5] thieno-[3,2-d]pyrimidine-2,4(1H,3H)-dione; ABT-980) was tested in radioligand binding assays, isolated tissue bioassays, intraurethral pressure (IUP) tests in isoflurane-anesthetized dogs, and blood pressure analyses in spontaneously hypertensive rats (SHR). Fiduxosin had higher affinity for cloned human α1a- (0.16 nM) and α1d-adrenoceptors (0.92 nM) in radioligand binding studies compared with α1b-adrenoceptors (25 nM) or in isolated tissue bioassays [pA2 values of 8.5–9.6 for α1A-receptors in rat vas deferens or canine prostate strips, 8.9 at α1D-adrenoceptors (rat aorta), compared with 7.1 at α1B-adrenoceptors (rat spleen)]. Furthermore, the compound antagonized putative α1L-adrenoceptors in the rabbit urethra (pA2value of 7.58). Fiduxosin blocked epinephrine-induced increases in canine IUP (pseudo-pA2 value of 8.12), eliciting only transient decreases in mean arterial blood pressure (MAP) in SHR. The area under the curve (AUC0→60 min) for the hypotensive response was dose related with a log index value for fiduxosin of 5.23, indicating a selectivity of 770-fold comparing IUP to MAP effects. Preferential antagonism of α1A- and α1D- versus α1B-adrenoceptors in vitro, blockade of putative α1L-sites in vitro, and selective effects on lower urinary tract function versus blood pressure in vivo by fiduxosin suggest the potential utility of this compound for the treatment of BPH.Keywords
This publication has 35 references indexed in Scilit:
- Effect of Fiduxosin, an Antagonist Selective for α1A- and α1D-Adrenoceptors, on Intraurethral and Arterial Pressure Responses in Conscious DogsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- In vitro and in vivo uroselectivity of B8805-033, an antagonist with high affinity at prostatic α 1A - vs. α 1B - and α 1D -adrenoceptorsNaunyn-Schmiedeberg's Archives of Pharmacology, 2001
- Pharmacological characterization of A-131701, a novel ?1-adrenoceptor antagonist selective for ?1A- and ?1D-compared to ?1B-adrenoceptorsDrug Development Research, 1998
- Molecular cloning, genomic characterization and expression of novel human α1A‐adrenoceptor isoformsFEBS Letters, 1998
- Cardiovascular Effects of Alpha-Blockers Used for the Treatment of Symptomatic BPH: Impact on Safety and Well-BeingEuropean Urology, 1998
- Tumour necrosis factor-αexpression and cell recruitment in Sephadex particle-induced lung inflammation: effects of dexamethasone and cyclosporin ABritish Journal of Pharmacology, 1997
- Decreased blood pressure response in mice deficient of the α 1b -adrenergic receptorProceedings of the National Academy of Sciences, 1997
- MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIAAnnual Review of Medicine, 1997
- ?1 Adrenoceptor subtypes: A synopsis of their pharmacology and molecular biologyDrug Development Research, 1996
- Pharmacological antagonism of ?-adrenergic agonist induced increases in canine intraurethral pressure in vivoDrug Development Research, 1995